Pfizer Inc. (ETR:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 125.21B |
| Revenue (ttm) | 53.69B |
| Net Income (ttm) | 8.41B |
| Shares Out | n/a |
| EPS (ttm) | 1.48 |
| PE Ratio | 14.90 |
| Forward PE | 8.69 |
| Dividend | 1.53 (6.95%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 27,888 |
| Average Volume | 49,305 |
| Open | 22.07 |
| Previous Close | 22.12 |
| Day's Range | 21.99 - 22.36 |
| 52-Week Range | 18.57 - 26.54 |
| Beta | 0.42 |
| RSI | 53.56 |
| Earnings Date | Feb 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Forget Teladoc and Buy This Healthcare Stock Instead
Teladoc and Pfizer have both faced challenges over the past few years. While the latter has a clear path to recovery, the former doesn't seem to.
Morgan Stanley Lowers Pfizer (PFE) Price Target to $28 | PFE Stock News
Morgan Stanley Lowers Pfizer (PFE) Price Target to $28 | PFE Stock News
Pfizer (PFE) Maintains Quarterly Dividend with 6.67% Yield
Pfizer (PFE) Maintains Quarterly Dividend with 6.67% Yield
Pfizer declares $0.43 dividend
Pfizer Declares First-Quarter 2026 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to hol...
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.
Keep your expectations in check.
The Best Turnaround Stock to Invest $1,000 in Right Now
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.
Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends
The Dividend Harvesting Portfolio remains up 32.60% on invested capital, yielding 8.02%, despite a temporary dip in dividend income from the MSTY reverse split. A dovish Fed rate cut and bullish GDP p...
Pre-Market Most Active for Dec 12, 2025 : KPLT, INTC, FRMI, FISV, CMCSA, NVDA, TE, PFE, GLW, ORCL, BAC, DXYZ
The NASDAQ 100 Pre-Market Indicator is down -114.23 to 25,572.45. The total Pre-Market volume is currently 97,998,861 shares traded.The following are the most active stocks for the pre-market session:...
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial
Pfizer's Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment, according to...
Hot Picks: Large-cap health care stocks to watch for dividend growth
Portfolio manager highlights AbbVie, Pfizer and Medtronic as compelling large-cap health care dividend plays with growth and valuation support.
IDEAYA Hits Full Enrolment In Pivotal Trial Of Darovasertib For Metastatic Uveal Melanoma
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA) has announced the completion of targeted full enrolment of 435 patients in its OptimuUM-02 Phase 2/3 trial, evaluating Darovasertib in combination with Pfiz...
3SBio Sells Shares, Divests Subsidiary To Boost Capital
After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary Key takeaways: 3SBio is proactively b...
EQS Newswire: Town Health International Medical Group Limited: Town Health & Pfizer Join Forces to Promote Territory-wide Respiratory Health Education
EQS Newswire / 11/12/2025 / 17:30 UTC+8 Town Health Charity Foundation Donates 20-valent Pneumococcal Conjugate Vaccines TWGHs Collaborates on Community Vaccination (Hong Kong, 11 December, 2025) ...
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.
Pfizer To Cut Over 200 Jobs In Switzerland As Cost-Reduction Plan Accelerates
WASHINGTON (dpa-AFX) - Pfizer is getting ready to cut hundreds of jobs in Switzerland as part of a long-term cost-saving plan, according to Bloomberg's report from Wednesday, which cites sources c...
Pfizer's Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer
Pfizer Inc. (NYSE: PFE) on Wednesday shared detailed results from the Phase 3 HER2CLIMB-05 trial of Tukysa (tucatinib) as part of an investigational first-line maintenance treatment combination, foll...
Pfizer (PFE) to Slash Swiss Workforce Amid Cost-Cutting Efforts
Pfizer (PFE) to Slash Swiss Workforce Amid Cost-Cutting Efforts
Pfizer is reportedly shedding hundreds of jobs in Switzerland
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports
Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.
Pfizer (PFE) Reports Positive Phase 3 Trial Results for Tukysa in Breast Cancer
Pfizer (PFE) Reports Positive Phase 3 Trial Results for Tukysa in Breast Cancer
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA (tucatinib) as part of an investigational first-line maintenance tr...
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigation...
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.